Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation

Haematologica

Volumn 85, Issue 10, 2000, Pages 1072-1082

  Roman, J ^a   Alvarez, M A ^a   Torres, A ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

BCR ABL; BMT; CML; DLI; PCR; Relapse

Indexed keywords

BCR ABL PROTEIN; HYDROXYUREA; INTERFERON;

ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; DECISION MAKING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID, CHRONIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033764427     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Bone marrow transplantation for chronic myeloid leukemia: Long-term results. Chronic Leukemia Working Party of the European Group of Bone Marrow Transplantation
2. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk for relapse associated with T-cell depletion
3. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens
4. Graft-versus-leukemia effect of donor lymphocytes transfusions in marrow grafted patients
5. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia from graft-versus-host disease
6. Sequential molecular monitoring of chimerism in chronic myeloid leukemia patients receiving donor lymphocyte transfusions for relapse after bone marrow transplantation
7. Detection of residual BCR/ABL transcripts in chronic myeloid leukaemia patients in complete remission using the polymerase chain reaction and nested primers
8. Expression of bcr-abl fusion transcripts following bone marrow transplantation for Philadelphia chromosome-positive-leukemia
9. Detection of residual leukemia after bone marrow transplantation for chronic myeloid leukemia: Role of polymerase chain reaction in predicting relapse
10. Persistence of bcr-abl gene expression following bone marrow transplantation for chronic myelogenous leukemia in chronic phase
11. Apparent decrease and elimination of BCR/ABL mRNA-expressing residual cells in patients with chronic myelogenous leukemia after allogeneic bone marrow transplantation
12. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia
13. Minimal residual disease status in transplanted chronic myelogenous leukemia patients: Low incidence of polymerase chain reaction positive cases among 48 long disease-free subjects who received unmanipulated allogeneic bone marrow transplants
14. Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation
15. Prognostic significance of Philadelphia chromosome positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplantation for chronic myelogenous leukemia
16. Long persistent BCR-ABL positive transcript detected by polymerase chain reaction after bone marrow transplant for chronic myelogenous leukemia without clinical relapse: A study of 64 patients
17. Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia following allogeneic and syngeneic bone marrow transplantation
18. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia
19. Presence or re-appearance of BCR-ABL-positive cells years after allogeneic bone marrow transplantation for chronic-phase chronic myelogenous leukemia in patients in hematological remission
20. Minimal residual disease in bone marrow transplant recipients with chronic myeloid leukemia
21. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia
22. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic bone marrow transplantation for chronic myeloid leukemia: Results and implications in 346 patients
23. Detection of bcr-abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation
24. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia
25. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
26. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction
27. Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation
28. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation
29. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia
30. Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia
31. Kinetics of increasing BCR-ABL transcript number in chronic myeloid leukemia patients who relapse after bone marrow transplantation
32. Simple competitive two-step RT-PCR assay to monitor minimal residual disease in CML patients after bone marrow transplantation
33. Debate round table. Monitoring of residual disease in chronic myelogenous leukemia: Methodological approaches and clinical aspects
34. Evaluation of mixed chimerism by in vitro amplification of dinucleotide sequences using the polymerase chain reaction
35. Amplification by the polymerase chain reaction of hypervariabie regions of the human genome for evaluation of chimerism after bone marrow transplantation
36. Mixed chimerism after bone marrow transplantation and the risk of relapse
37. Detection of minimal residual disease and persistence of host-type hematopoiesis: A study in 28 patients after sex-mismatched non-T-cell depleted allogeneic bone marrow transplantation for Philadelphia chromosome positive chronic myelogenous leukemia
38. Persistent donor chimaerism is consistent with disease-free survival following BMT for chronic myeloid leukemia
39. Importance of mixed chimerism to predict relapse in persistently bcr-abl positive long survivors after allogeneic bone marrow transplantation for chronic myeloid leukemia
40. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft
41. Increasing mixed haematopoietic chimaerism after BMT with total depletion of CD4+ and partial depletion of CD8+ lymphocytes is associated with a higher incidence of relapse
42. Molecular analysis of lineage specific chimerism and minimal residual disease by RT-PCR of P210 bcr-abl and P190 bcr-abl after allogeneic bone marrow transplantation for chronic myeloid leukemia: Increasing mixed myeloid chimerism and P190 bcr-abl detection precede cytogenetic relapse
43. Complete donor T cell chimerism is accomplished in patients transplanted with bone marrow containing a fixed low number of T cells
44. Consistent amounts of acute-leukemia-associated P190 BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis
45. P190 BCR-ABL mRNA is expressed at low levels in P210-positive chronic myeloid and acute lyrephoblastic leukemias
46. Expression of P210 and P190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia
47. A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukemia
48. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia
49. Donor leukocyte infusions
50. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case forgiving donor leukocyte transfusions before the onset of hematologic relapse
51. Allogeneic cell therapy with donor peripheral blood cells and recombinant interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation
52. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: Apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression
53. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation
54. Use of interferon alpha-2a to treat hematologic relapse of chronic myelogenous leukemia after bone marrow transplantation
55. Recombinant alpha-interferon as treatment For chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: A report from the Societe Francaise de Greffe de Moelle
56. Interferon therapy For Ph1 positive CML patients relapsing after T cell-depleted allogeneic bone marrow transplantation
57. Use of α-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation
58. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
59. Adoptive immunotherapy For recurrent CML after BMT
60. Interferon-α and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation
61. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose
62. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation
63. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia
64. Treatment of relapse after allogeneic BMT with donor leukocyte infusions in 16 patients
65. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
66. Outcome of donor leukocyte infusion (DLI) for relapse after BMT is dependent on the indication For transplantation and chimerism oft lymphocytes
67. Adoptive immunotherapy For relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: Equal efficacy of lymphocytes from sibling and matched unrelated donors
68. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions
69. Toxicity and efficacy of defined doses of CD4+ donor lymphocyte for treatment of relapse after allogeneic bone marrow transplant
70. CD8-depleted lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogenic bone marrow transplantation
71. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia
72. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: Lack of residual donor hematopoiesis predicts aplasia
73. Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF mobilized peripheral blood stem cell preparation
74. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation
75. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
76. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes
77. T-cell-depleted bone marrow transplantation for acute leukaemia. Using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse
78. T-cell depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect
79. The influence of intensifying the conditioning regimen and the impact of pre-emptive donor leukocyte infusions after T-cell depleted BMT
80. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions
81. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia
82. Second HLA-identical sibling transplants for leukemia recurrence
83. Relapse of leukemia after bone marrow transplantation: Effect of second myeloablative therapy